← All trials
NCT05590195
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2022
- Primary completion
- Dec 1, 2024
- Completion date
- Mar 1, 2025
- First posted
- Oct 21, 2022
- Last posted
- Oct 21, 2022
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Western OntarioLead sponsor
- University of Western OntarioCollaborator
- University of Western OntarioCollaborator
- University of Western OntarioOverall official - principal investigator
- University of Western OntarioSponsor investigator
- Deerland EnzymesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.